Each year as we approach summer, biotech investors search for the elusive companies that will have the largest pops at the summer oncology conferences in order to reap the rewards of their play. We saw this play out with Iovance Biotherapeutics (IOVA) who popped 36% on the release of its ASCO data. For a complete overview of the ASCO Conference timelines, please read my previous article ASCO Alert: Stay Ahead of the Updates. Despite abstracts being released, I am still eyeing one company with a late-breaking abstract, that being Seattle Genetics (SGEN). Here, I will outline Seattle Genetics ASCO . . .
About Chris Stang
As a young investor, I focus developing biotech companies. I focus strongly on fundamentals, digging deeper to understand the financial and regulatory position of companies. The biotechnology sector is very volatile, please use caution and do your own additional due diligence before investing. I also secondarily focus on small security and defense companies that provide long-term growth opportunities.